Latest Oxford BioMedica Stories
KVISTGARD, Denmark, May 9 /PRNewswire-FirstCall/ -- Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed.
KVISTGAARD, Denmark, March 27 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's Annual Report 2008.
KVISTGARD, Denmark, January 12 /PRNewswire-FirstCall/ -- Bavarian Nordic owns several United States patents relating to an attenuated strain of the company's core technology, MVA-BN(R), which is the basis for its smallpox vaccine, IMVAMUNE(R).
GeneThera, Inc. (PINKSHEETS: GTHR) announced today that has tendered a new offer for the acquisition of Oxford Biomedica Plc. Commenting on the news GeneThera Chairman Dr. Tony Milici, M.D., Ph.D.
GeneThera, Inc. (PINKSHEETS: GTHR), a molecular biotechnology company focused on the detection and treatment of disease in live animals using state-of-the-art technology, is pleased to issue this informational release to its shareholders.
Oxford BioMedica has announced that the independent data safety monitoring board for the Phase III Trist study of TroVax in renal cancer has recommended that the trial should continue but that further vaccinations be discontinued.
- Withering but not falling off, as a blossom that persists on a twig after flowering.